semaglutide tirzepatide weight loss and Injectable Correlated with Greatest Among GLP-1 Medications Tirzepatide outperformed semaglutide weight-loss drug

With files from Ariel Tozman

(Nasdaq: LEXX & LEXXW) (the Company or Lexaria), a global innovator in drug delivery platforms announces additional positive interim results from a human pilot study (the Study) evaluating DehydraTECHTM technology for the oral delivery of the glucagon-like peptide-1 (GLP-1) drug semaglutide available commercially in the branded product Rybelsus, further to its previously announced findings from this work

The expansion aims to produce injectables for obese patients and other serious chronic diseases

Why Half-Life Matters for Your Treatment Plan Understanding semaglutide's half-life helps explain why missing a dose creates minimal immediate impact compared to missing daily medications